How Long Does an IVF Process Take: Stim Protocols

You were handed a calendar with "antagonist protocol" or "long Lupron" written at the top and a stack of medication boxes that did not come with an explanation. This post is the menu: what each protocol is, why a reproductive endocrinologist (RE) would pick it for one body and not another, and how long does an IVF process take once you account for which protocol your clinic chose.

Why there are different protocols at all

Stimulation has two simultaneous goals. The first is to grow many follicles to mature size at the same time, so that egg retrieval yields a useful cohort rather than the single egg a natural cycle produces. The second is to prevent your pituitary from triggering its own luteinising hormone (LH) surge before retrieval, because a premature surge ovulates the follicles into your pelvis instead of letting them be retrieved in theatre.¹

The drugs we use to control that LH surge are the dividing line between protocols. GnRH agonists like Lupron (leuprolide) shut the pituitary down by overstimulating it into desensitisation. GnRH antagonists like Cetrotide and Ganirelix block the gonadotropin-releasing hormone (GnRH) receptor directly and reversibly.² The choice between these two mechanisms, combined with starting position (ovarian reserve, age, previous response, scheduling needs), drives which named protocol you end up on. There are five common flavours, and once you can name them you can finally ask why your RE chose yours.

The five named protocols

Long agonist protocol (long Lupron)

The long protocol starts in the mid-luteal phase of the cycle before your stim cycle, usually around day twenty-one. You begin daily Lupron injections, and over the next ten to fourteen days the pituitary is down-regulated, first flared, then suppressed. Your clinic confirms suppression with an estradiol level and a thin endometrial lining on scan. Only then does stimulation with gonadotropins begin, lasting another ten to twelve days until trigger.¹

The strengths of this protocol are control and predictability. Cycles can be scheduled months in advance because the down-regulation locks the timeline. Premature LH surges are rare. Historically it has been the default in patients with endometriosis, on the theory that suppression dampens disease activity in the months around treatment.

The trade-offs are real. The cycle is long. There are more total injections. The risk of ovarian hyperstimulation syndrome (OHSS) is higher than in antagonist cycles, because the suppressed pituitary cannot be used for a Lupron trigger at the end. You have to trigger with human chorionic gonadotropin (hCG), which is the main driver of OHSS.³

Antagonist protocol (the modern default)

In an antagonist cycle, gonadotropins start on cycle day two or three of the stim cycle itself, with no prior down-regulation. The antagonist, Cetrotide or Ganirelix, is added five to six days into stim, or when the lead follicle reaches twelve to fourteen millimetres, whichever comes first.² Trigger is given when two or three lead follicles are at seventeen to twenty millimetres.

This is now the most common protocol in most modern clinics, and for good reason. It is shorter. There are fewer total injections. Live birth rates are non-inferior to long-agonist cycles across a large Cochrane analysis,² and in PCOS responders the antagonist protocol may be the safer default because it allows a GnRH agonist trigger instead of hCG, which dramatically reduces OHSS risk.³

Its trade-off is mostly logistical: scheduling is more reactive than the long protocol. You start when your period starts. You cannot pre-commit to a retrieval week three months out.

Microdose flare (microdose Lupron) protocol

The microdose flare uses low-dose Lupron from cycle day two, alongside gonadotropins started the same day. The idea is that the initial Lupron "flare" (the brief surge of pituitary FSH and LH that happens in the first day or two before suppression) gives your ovaries an extra push before suppression kicks in. It is used almost entirely in poor responders, especially those with prior cycles that failed to produce enough follicles.

Strengths: maximises endogenous FSH at the start of stim, which can sometimes recruit follicles that a standard antagonist cycle would have missed. Trade-offs: higher cancellation rate if the follicles still do not recruit, and longer time on injections than antagonist.

Mini-IVF and mild stimulation

Mini-IVF uses much lower gonadotropin doses, often seventy-five to one hundred and fifty international units per day, sometimes paired with oral letrozole or clomiphene to do part of the work. The deliberate aim is three to six eggs per retrieval rather than twelve to twenty. It is a strategic choice, not a fallback.

For patients on a budget, patients who have had OHSS before, some patients with diminished ovarian reserve where pushing harder produces no more eggs, and patients with a philosophical preference for fewer medications, mini-IVF can be a reasonable choice. The trade-off is honest: yield per retrieval is lower, and building a euploid embryo bank usually takes more cycles than a conventional protocol would.

Natural cycle IVF

Natural cycle IVF uses no stimulation at all. The clinic monitors your spontaneous cycle and retrieves the single dominant follicle, usually triggered with a small dose of hCG or by the natural LH surge. It produces, at best, one egg per cycle, with a high cancellation rate because dominant follicles can ovulate before scheduled retrieval. It is used mainly in very poor responders where stimulation produces no additional eggs, and in patients for whom religious or philosophical reasons rule out conventional stim.

How REs actually choose between them

Protocol selection is one of the few areas in IVF where reasonable doctors will disagree, and reasonable doctors will sometimes change their preferences across a career.¹ If your first cycle did not work, do not assume the protocol was wrong, but do ask why we are or are not changing it.

In practice, the choice is driven by four factors.

Anti-Müllerian hormone (AMH) and antral follicle count (AFC) do most of the work. High AMH (above three and a half nanograms per millilitre) and high AFC (above twenty-four) push toward antagonist with planned agonist or dual trigger. Low AMH (below one) and low AFC (below six) push toward microdose flare or mini-IVF.

Previous response is the next strongest signal. A patient who hyperstimulated last time will be on a lower dose and an antagonist protocol regardless of AMH. A patient who produced two eggs last time on standard stim is a candidate for a different approach, not a higher dose of the same one.

Age and body mass index (BMI) affect dose more than they affect protocol choice. Older patients and those with higher BMIs typically need a higher starting dose for the same response. But age does not by itself dictate which named protocol.

Scheduling matters more than people admit. A patient who needs a retrieval in a specific calendar window for work, school, or surgery sometimes gets the long protocol because it can be scheduled. Most cycles do not need that.

If you have polycystic ovary syndrome (PCOS), high AMH, or have had OHSS before, you should be on an antagonist protocol with a plan for agonist or dual trigger from the start, not as a rescue when the estradiol climbs.³ The PCOS-specific IVF playbook walks through why.

How long does an IVF process take

This is the most common search for this phase, and the answer depends almost entirely on which protocol you are on.

For an antagonist cycle, the stimulation phase is ten to twelve days. Add the trigger shot, thirty-five to thirty-six hours until retrieval, and the typical five-day window to a fresh transfer or freeze-all decision, and the medication-heavy portion of one cycle runs about three weeks from cycle day one.¹

For a long-agonist cycle, add ten to fourteen days of Lupron down-regulation before stim. The cycle as a whole is four to five weeks of active medication.

For mini-IVF, stim is similar in length to an antagonist cycle but with fewer injections per day.

For the whole IVF process from start to finish, including the consult, baseline labs, mock transfer, hysteroscopy if needed, ordering medications, and then the stim cycle itself, allow two to three months from first appointment to first retrieval. Add another four to eight weeks if you are doing a freeze-all and then a separate frozen embryo transfer cycle. If you are doing pre-implantation genetic testing for aneuploidy (PGT-A), add roughly two weeks for the embryology lab to biopsy and the genetic lab to run the assay before transfer.

Egg retrieval itself, the procedure, takes about twenty to thirty minutes under sedation, with another hour or two in recovery before discharge.

Trigger options: dual, agonist, hCG

The trigger shot does the final maturation of eggs and times retrieval. There are three options, and the choice matters more for OHSS risk than most patients realise.

hCG trigger (Ovidrel, Pregnyl, Novarel) is the original standard. It mimics the LH surge and produces a very long-acting maturation signal. It is straightforward but carries the highest OHSS risk because hCG persists in circulation for days and continues to stimulate the ovaries past retrieval.³

GnRH agonist trigger (Lupron in an antagonist cycle) gives a short, physiological LH surge from the patient's own pituitary. OHSS risk is near zero. The trade-off is that the luteal phase is short and weak, so fresh transfers after agonist trigger typically need intensive progesterone and estrogen support, and many clinics simply freeze all and transfer in a separate cycle.⁴

Dual trigger combines low-dose hCG with a Lupron trigger. The hope is to preserve some of the maturation benefit of hCG while keeping OHSS risk low. Evidence is growing, and it is now common practice in high responders where the clinic still wants a fresh transfer.

Long-protocol patients cannot use a Lupron trigger because their pituitary is suppressed. They have to trigger with hCG. This is the main reason long-protocol cycles are no longer the default in PCOS patients or high responders.

What might change between cycles

If you are on cycle two, the question is not usually "different protocol" but "different dose, different trigger". The most common adjustments in second cycles are:

• Dose changes: a high responder gets less FSH; a slow responder gets more, sometimes with added LH activity.
• Trigger type: a patient who had any OHSS warning signs in cycle one is moved to agonist or dual trigger.
• Luteal support intensification: adding intramuscular progesterone in oil, adjusting estradiol support, sometimes adding low-dose hCG boosters.
• A genuine protocol switch: less common, but reasonable after one cycle of data, for example moving from a standard antagonist to a microdose flare if response was poor.

The point I want to make in clinic, and want to make here, is that one cycle is one data point. Most of the useful learning from cycle one is about your specific responder profile, not about the protocol itself.

What to ask your RE

These four questions clarify your protocol better than anything else, and they also sharpen the answer to how long does an IVF process take in your specific case.

1. Which protocol am I on, and why was it chosen for my AMH and AFC?
2. What is my starting dose, and what is the target follicle count we are aiming for?
3. What trigger are you planning, and what would shift you toward agonist or dual trigger mid-cycle?
4. What is the cancellation threshold for my cycle, on both the low and the high end?

What's next

• If you want the walk-through of what stim actually feels like: IVF Stimulation Phase: What the 10 to 14 Days Actually Feel Like
• If your concern is the injections themselves: Injections in IVF: Self-Injecting and What to Expect
• If you are at risk for OHSS or have already started worrying: OHSS: Ovarian Hyperstimulation Syndrome and How Doctors Prevent It
• If you have PCOS or a high AMH: Why PCOS Patients Get More Eggs and the OHSS Risk
• If a cycle did not move forward: When Things Don't Go to Plan

Sources

1. ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open 2020;2020(2):hoaa009. https://doi.org/10.1093/hropen/hoaa009
2. Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews 2016;4(4):CD001750. https://doi.org/10.1002/14651858.CD001750.pub4
3. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility 2016;106(7):1634-1647. https://doi.org/10.1016/j.fertnstert.2016.08.048
4. Engmann L, DiLuigi A, Schmidt D, et al. The use of GnRH agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing IVF prevents the risk of ovarian hyperstimulation syndrome. Fertility and Sterility 2008;89(1):84-91. https://doi.org/10.1016/j.fertnstert.2007.02.002
5. Lambalk CB, Banga FR, Huirne JAF, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Human Reproduction Update 2017;23(5):560-579. https://doi.org/10.1093/humupd/dmx017
6. Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertility and Sterility 2011;96(5):1058-1061.e7. https://doi.org/10.1016/j.fertnstert.2011.09.048